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Abstract
Mesenchymal stromal cell [MSC] therapy is a new treatment for perianal fistulas in Crohn’s disease. 
Although MSC therapy shows a favourable safety profile, long-term safety data are limited. We 
detected an Epstein Barr virus [EBV]-associated B cell lymphoproliferative lesion in the rectum 
of a patient 4  years after local administration of MSCs for his perianal fistulas. To investigate 
whether MSC therapy contributed to the development of this lymphoproliferative disease, we 
analyzed the possibility of EBV transfer via the MSC product and the persistence of MSCs in the 
lymphoproliferative lesion using short tandem repeat analysis.
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1. Introduction
In 2014, we conducted a dose-finding placebo-controlled clin-
ical trial in which allogeneic bone marrow–derived mesenchymal 
stromal cells [MSCs] were administered locally to Crohn’s disease 
[CD] patients with refractory perianal fistulas.1 Fistula healing at 
week 6 was observed in 80% of the patients treated with 30 × 106 
MSCs, compared with 17% in the placebo group. Four years later, 
we invited 20 study patients for long-term follow-up and performed 
endoscopy of the rectum and pelvic MRI. Here, we report a case 
of lymphoproliferative disease [LPD] in the rectum detected 4 years 
after MSC therapy for perianal fistulizing CD.
2. Case report
One of the patients treated with a local injection of 30 × 106 MSCs 
was a 45-year-old man. In 2008, he was diagnosed with CD of the 
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Figure 1. LPD in the rectum of patient previously treated with local MSC therapy. [A] Ulcer in the rectum with a raised edge next to the scar of the old fistula 
opening after biopsy. [B] Routine immunohistochemistry performed on biopsy from the lesion using the classical markers PAX5, CD20, CD30, CD15, and CD45. 
In situ hybridisation [dark staining] for Epstein-Barr encoding region [EBER] to detect EBV in the lesion. [C] MRI-scan of the abdomen within the coronal plane 
para-aortal multiple lymphoproliferative processes around the a. mesenterica inferior and in the axial plane multiple lymphoproliferative processes surrounding 
the a. and v. iliaca interna.
colon, predominantly left-sided. In 2012, he developed a trans-
sphincteric fistula with one internal and two external openings. He 
was treated with prednisone [2008], azathioprine [2008–2012], 
adalimumab [2011–2012], and methotrexate [2012–2017]. Since 
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MSC therapy in 2014, his fistula was closed. In 2016, he started with 
vedolizumab, which he has continued since, because of a luminal ex-
acerbation. Surveillance endoscopy in the summer of 2017 revealed 
no abnormalities and normal pathology of biopsies.
At the long-term follow-up visit, 4 years after MSC therapy, the 
patient reported no complaints and had a normal faecal calprotectin 
of 46 µg/g. The scheduled MRI at this visit showed fibrosis of the 
distal part of the fistula tract. The cranial part of the fistula was no 
longer visible. During scheduled proctoscopy, an ulcer next to the 
scar of the old fistula opening was seen with a raised edge. The diam-
eter was ~10 mm [Figure 1A]. Biopsies were obtained and histology 
revealed the presence of an Epstein-Barr virus [EBV]-associated B 
cell LPD [Figure 1B]. The lesion contained a combination of small 
lymphocytes and blastoid cells, positive for EBV-encoded RNA and 
expressing PAX-5, CD20, CD15, and to a lesser extent CD30 [Figure 
1B]. Laboratory tests showed a low level of EBV virus–specific DNA 
in his serum. Of note, our patient was IgG EBV–positive, but IgM 
EBV–negative at the time of MSC therapy in 2014. A  subsequent 
CT scan of the abdomen and thorax showed the presence of exten-
sive lymphadenopathy [Figure 1C]. The patient was diagnosed with 
Lugano Stage IV EBV-associated B cell LPD and was treated success-
fully with chemotherapy.
Retrospective analysis of the biopsies of the rectum taken in 2014 
excluded the presence of LPD prior to MSC administration, because 
no rectum localization of EBV could be detected using EBV-encoded 
RNA in situ hybridization. Next, we investigated a potential role 
for MSC therapy in the development of this LPD, considering the 
following options: 1. Transfer of LPD via the MSC Drug Product; 
2. Transfer of EBV via the MSC Drug Product; 3. Tumorigenicity due 
to persisting local allogeneic MSCs. Regarding the first option, the-
oretically, an LPD present in the MSC Drug Product could be trans-
ferred to the patient. However, no CD45+ cells, and thereby B cells, 
were detected in the MSC Drug Product [10 000 cells screened]. This 
was in accordance with the release criteria for MSC Drug Products 
generated for this study [≤1% CD45+ cells]. Additionally, all treating 
physicians of all other patients who received an MSC Drug Product 
obtained from the same donor [n = 9, Table 1] were contacted about 
the potential presence of LPDs in their patients. No LPDs were re-
ported in the other patients treated with MSCs obtained from this 
donor bone marrow. Furthermore, at the time of bone marrow dona-
tion, the MSC donor was in good health, without any signs of LPD.
The MSC-donor was positive for IgG EBV at the time of bone 
marrow donation. To investigate a potential transfer of EBV-virus to 
the recipient using MSCs as a vehicle, the MSCs that were infused 
in the patient and two other MSC Drug Products obtained from 
donors positive for IgG EBV at the time of bone marrow donation 
were tested for the presence of EBV-specific DNA using PCR. No 
EBV-DNA was detected in the MSCs infused in this patient; nor was 
there any in the other Drug Products that were tested.
To investigate whether the injected MSCs were still present in 
the lesion in the rectum, flow cytometry sorting was used to separate 
cells in rectum biopsies into CD45+CD19dim/+ and CD45–CD15dim/+ 
cells [Figure 2A, panel A: representing healthy and malignant B-cells], 
and a CD45–CD15– fraction [Figure 2A, panel B: representing the 
stromal–epithelial population, which would include the allogeneic 
MSCs, if still present]. Standard short tandem repeat [STR] analysis 
was used to examine the presence of genomic material of the MSC 
donor in both sorted cell fractions, as well as in 20 000 unfrac-
tionated cells obtained from the same biopsy. Although cell counts 
and DNA recovery was low, some STR regions on nuclear DNA 
could be evaluated successfully. All fractions exclusively showed 
the STR profile of the patient. Together, these data indicated that 
no allogeneic MSCs were present in the biopsied rectal lymphoma 
[Figure 2B].
3. Discussion
In this report we present a patient diagnosed with LPD in the rectum 
4 years after local MSC therapy for perianal fistulizing CD. We hy-
pothesized that the occurrence of LPD in this patient could be ex-
plained by his underlying IBD, prolonged use of immunosuppressive 
medication, including methotrexate, vedolizumab, anti-tumor ne-
crosis factor [TNF]-therapy, and azathioprine, or local MSC infusion.
Studies on the risk of LPD in patients with IBD generated con-
flicting results. In contrast to rheumatoid arthritis, IBD itself does 
not seem to cause a statistically significant increased risk of LPD.2–6 
However, IBD patients using immunosuppressive medication have 
an increased risk of LPD.2 These LPDs are often extranodal and are 
the result of EBV-driven processes, although other infectious agents 
could also be involved.2,7 Our patient used several immunosuppres-
sive therapies in the last 10 years, and each of these treatments is 
associated with an increased risk of developing LPD. Until 5 months 
before LPD diagnosis, the patient was using methotrexate as an im-
munosuppressive therapy. Methotrexate-associated LPD is recog-
nized as an independent entity and is characterized by the presence 
of EBV virus in the lymphoma tissue. In most patients, a regression 
of the LPD is seen after discontinuation of methotrexate.8 At the 
time of LPD diagnosis, the patient was treated with vedolizumab. As 
vedolizumab has only been available for a few years, extensive data 
on the long-term safety profile are not available yet.9 Furthermore, 
our patient had used azathioprine for 4 years and anti-TNF therapy 
in the past. Although, current use of thiopurines in IBD is associ-
ated with an increased risk of LPD, conflicting data are available 
about the risk of LPD after withdrawing thiopurines and anti-TNF 
Table 1. Overview of other patients treated with MSCs from the same donor as our patient.
 Age at time of treatment (years) Gender Indication for MSC therapy Time of follow-up [months] LPD reported
1 33 V CD fistula, MSC-F trial 48 No
2 30 V CD fistula, MSC-F trial 48 No
3 22 M CD fistula, MSC-F trial 48 No
4 9 M GvHD, Study P05.089 5.5 No
5 10 V GvHD, Study P05.089 <1 No
6 15 V GvHD, Study P05.089 10 No
7 42 M GvHD, hospital exemption 50 No
8 39 V GvHD, hospital exemption 3.5 No
CD, Crohn’s disease; GvHD, steroid refractory graft-versus-host disease; LPD, lymphoproliferative disease; MSC-F trial,1 Study P05.089 [LUMC].19
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Figure 2. Analysis of the presence of allogeneic MSCs in the LPD in the rectum. [A] Flow cytometry sorting gating stragety for population [A] CD45+CD19dim/+ and 
CD45-CD15dim/+ cells and [B] CD45–CD15– cells. [B] Peak profile of short tandem repeat marker D3S1358 in the DNA of the MSC-donor and patient, obtained from 
white blood cells [WBCs], and in the DNA from the rectum biopsy and the two sorted populations [A and B] out of the biopsy.
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treatment.2,10–13 Therefore, we cannot exclude the possibility that the 
patient developed LPD as a result of immunosuppressive therapy 
other than a single MSC gift in 2014.
As MSCs have immunomodulatory properties and may have 
served as a vehicle for EBV-transfer, we investigated the potential 
role of MSC therapy in this LPD. We excluded the possibility that 
the EBV virus was transferred via the infused MSC or by contam-
inating EBV-positive B cells present in the MSC Drug Product. 
Furthermore, we did not detect any allogeneic MSCs or DNA spe-
cific for the MSC donor in the lesion in the rectum. No data are 
available on the risk of LPD in patients who have received MSC 
therapy. Overall, intravenous MSC therapy does not seem to be 
associated with significant immunosuppression in immunocom-
petent individuals.14 However, an additional immunosuppres-
sive effect in patients already on immunosuppressive medication 
cannot be excluded. In 52 renal transplant patients treated in our 
centre with intravenous MSCs, no LPD was reported [follow up 
6 months–4 years]. However, in the literature, two cases of EBV-
associated LPD after systemic MSC treatment are described in 
patients with Graft-versus-Host Disease,15,16 a severely immuno-
compromised patient population. No data are available on LPD 
following the local injection of MSCs.
Taken together, it is highly unlikely that this EBV-associated LPD 
was directly related to MSC therapy, but rather it is likely to have 
been the result of prolonged immunosuppressive therapy. However, 
we cannot exclude the possibility of additional local immunosup-
pression by MSC therapy, which subsequently may drive prolifer-
ation of tissue-resident EBV-infected cells. Darvadstrocel,17 a product 
containing MSCs isolated from adipose tissue, is now approved in 
Europe as a treatment for complex perianal fistulas in patients with 
Crohn’s disease. One year follow-up data showed a favorable safety 
profile of this product.18 This case report shows that more long-term 
reports on MSC therapy in perianal fistulas from clinical trials and 
daily practice are needed to evaluate the complete safety profile of 
topical MSC therapy.
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